Engflag

Fucou

Quick links to important sections

Fucou

Fucou_EN

Treatment option:

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Fucou

Quick Facts

Property Description
Active Ingredients Dextromethorphan Hbr, Potassium Cresolsulfonate, Lysozyme Cl
Form Oral Solid (Capsule or Tablet)
Pharmacological Class Combination Antitussive and Expectorant
Common Use Relief of Acute Cough Symptoms
Origin Semi-synthetic (Dextromethorphan), Salt (Expectorant), Enzyme (Lysozyme)

What Type of Medicine is Fucou?

Fucou is accurately defined as a fixed-dose combination product designed for administration via the oral route. It is classified within the respiratory therapeutic category as a Combination Antitussive and Expectorant, a structure which provides a dual approach to managing cough symptoms. This formulation is distinguished by its integration of three distinct active compounds, offering a combined pharmacological strategy beyond single-ingredient or simple dual-action preparations.

Understanding Fucou’s Three Active Components

The drug's functionality is directly tied to its three active ingredients. Dextromethorphan Hydrobromide is a semi-synthetic derivative that is clinically recognized for its antitussive efficacy by suppressing the central cough reflex. Potassium Cresolsulfonate acts as the classic expectorant salt, improving the hydration and volume of respiratory secretions. Lysozyme Chloride provides the final component, a naturally occurring enzymatic protein that supports the integrity of the mucous membranes and assists in mucus breakdown. This combination is useful because it addresses the symptomatic urge to cough while simultaneously managing the physical congestion often accompanying it.

The General Purpose of Fucou’s Combination

The general purpose of Fucou is to provide comprehensive relief from acute cough and associated bronchial irritation. This dual-action mechanism utilizes Dextromethorphan to reduce the central stimulation of the cough, while the expectorant and enzyme components enhance the peripheral clearance of thick secretions. The formulation is positioned to address the general respiratory discomfort experienced during a typical cough, such as those accompanying a cold or mild respiratory inflammation.

What side effects are possible with Fucou?

Possible Side Effects and Safety Information

The safety profile for Fucou, based on its combined active ingredients, is officially documented by government regulatory bodies and covers potential adverse reactions classified by frequency and physiological system. This information is intended to communicate the medicine's risk profile without providing clinical advice.

Documented Adverse Reactions and Classification

The most commonly documented adverse reactions involve the Nervous System and the Gastrointestinal System. Common effects can include dizziness and somnolence (drowsiness), as well as gastrointestinal disturbances like nausea and vomiting.

System-Organ Class Common Adverse Reactions
Nervous System Disorders Dizziness, Somnolence
Gastrointestinal Disorders Nausea, Vomiting
Skin Disorders Rash, Urticaria (Hives)

Serious Safety Considerations and Restrictions

Official labeling highlights the potential for serious adverse reactions. These include potentially life-threatening conditions such as Serotonin Syndrome, which is a severe safety concern associated with the antitussive component when co-administered with certain other drugs, and severe hypersensitivity reactions, including anaphylaxis, to any of the formulation's constituents.

Regulatory documents establish safety-related restrictions on use. Fucou is strictly contraindicated for use in patients who are currently taking or have recently discontinued (within 14 days) a Monoamine Oxidase Inhibitor (MAOI) due to the risk of Serotonin Syndrome. Specific safety considerations are also noted for older adults who may show increased sensitivity to the central nervous system effects, and caution is advised for individuals with severe hepatic or renal impairment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documents define the overdose profile of Fucou by its potential for severe central nervous system (CNS) and systemic effects. An overdose may present with a range of acute symptoms, including profound drowsiness, mental confusion, agitation, hallucinations, nystagmus, tremor, and an unsteady gait (ataxia). Additional documented signs include gastrointestinal issues such as nausea and vomiting, changes in heart rhythm (tachycardia), and elevated body temperature (hyperthermia).

Overdose exposure carries a risk of life-threatening complications, specifically severe respiratory depression, generalized seizures, coma, and the potential development of Serotonin Syndrome (marked by pyrexia and excitation). Due to the severity of these documented outcomes, regulatory authorities mandate that quick medical attention is critical for all suspected exposures, even if initial symptoms are not yet apparent.

Immediate Medical Action is Required:

  • Seek immediate medical attention for all suspected overdose scenarios.
  • Contact a Poison Control Center immediately.
  • Emergency services should be called if an individual exhibits severe signs such as collapse, difficulty breathing, seizures, or is unable to be awakened.

Management procedures described in official labels focus on professional, symptomatic and supportive care. Specific interventions, such as the use of activated charcoal or the antagonist Naloxone for severe CNS or respiratory depression, are conducted under medical supervision. The risk of toxicity is increased in certain groups, notably patients who are poor CYP2D6 metabolizers.

Therapeutic Uses of Fucou

What Fucou Treats: Main Uses and Benefits

Fucou is a combination therapy commonly applied in contexts where short-term symptomatic assistance is needed for respiratory discomfort. It is considered relevant in clinical settings marked by increased discomfort or tension caused by acute airway symptoms, used for managing symptom clusters that may appear suddenly or intensify over time. The primary uses of combination antitussive and expectorant products are well-established in providing temporary relief for symptoms of the common cold and flu.

The medication is commonly used across conditions presenting with acute episodes characterized by both irritative cough symptoms and productive chest congestion. This supportive therapeutic benefit provides support that helps ease the overall symptom burden and may help patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Dual Symptoms

Symptom Targeted Primary Benefit
Irritative Cough Suppression of the frequent urge to cough
Thick Mucus Facilitation of secretion clearance

Core Therapeutic Focus

Fucou may be part of symptomatic management in addressing the disruptive manifestations of cough, offering supportive relief, particularly when symptoms related to the cough interfere with comfort and rest. It is relevant in contexts involving heightened systemic burden and may assist with maintaining functional stability when symptoms result in noticeable physiological strain, which describes its role in managing acute cough and supporting mucus clearance.

Regulatory References

  1. Health Canada Non-prescription Oral Adult Cough, Cold and Flu Labelling Standard

Eligibility and Restrictions for Use

Who can and cannot use Fucou?

Eligibility for Fucou, a combination antitussive and expectorant, is defined by regulatory bodies primarily through age restrictions and specific medical contraindications, ensuring that the medicine is used only in appropriate populations.

Eligibility scope

Scope Element Official Regulatory Documentation Summary
Populations for whom use is allowed Adult patients and children 12 years and over for temporary relief of acute cough.
Populations for whom use is not recommended Children under 4 years of age (safety is not established); Patients with chronic cough or cough with excessive secretions.
Populations for whom use is contraindicated Patients currently or recently (*within 14 days) receiving Monoamine Oxidase Inhibitors (MAOIs); individuals with known hypersensitivity to any component; subjects at risk of developing respiratory failure.

Age-related and Conditional Eligibility Rules

  • Children under 4 years of age: Safety and efficacy have not been established by systematic clinical trials, and use is generally not recommended.
  • Chronic respiratory conditions: The medicine is contraindicated in patients with, or at risk of developing, respiratory failure or during an acute asthma attack.
  • Organ impairment: Caution is required in patients with hepatic impairment, and medical advice should be sought for those with severe renal impairment.
  • Pregnancy and lactation: Combination products are generally advised against during pregnancy and lactation unless specifically directed by a healthcare provider.

What should I know about interactions with other medicines?

Lisinopril's interaction profile requires specific monitoring when used alongside several classes of medicines, primarily due to the risk of hyperkalemia, hypotension, and angioedema.

Key Interacting Agents and Constraints

Interacting Category Official Constraint / Requirement
Potassium-Elevating Agents (e.g., potassium supplements, potassium-sparing diuretics, salt substitutes containing potassium) Frequent monitoring of serum potassium levels is required due to increased risk of hyperkalemia.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), including selective COX-2 inhibitors Periodic monitoring of renal function is necessary; coadministration may result in deterioration of renal function and can attenuate the antihypertensive effect.
Dual Renin-Angiotensin System (RAS) Blockade (e.g., Angiotensin Receptor Blockers, aliskiren) Generally avoided due to increased risks of hypotension, hyperkalemia, and renal impairment. Use with aliskiren is contraindicated in patients with diabetes.
Neprilysin Inhibitors (e.g., sacubitril) and mTOR Inhibitors (e.g., sirolimus) Increased risk of angioedema. Use of lisinopril with a neprilysin inhibitor is contraindicated, with a required 36-hour wash-out period when switching between these agents.
Lithium Serum lithium levels must be closely monitored during concurrent use, as lisinopril may decrease its clearance, leading to potential lithium toxicity.
Injectable Gold (Sodium Aurothiomalate) Use with injectable gold is associated with rare reports of a nitritoid reaction (including facial flushing, nausea, vomiting, and low blood pressure).

This structure reflects the mandated patient monitoring and use-restriction statements found within official government regulatory drug information. The established constraints govern safe coadministration, often requiring laboratory checks (potassium, renal function, lithium) to mitigate significant adverse outcomes.

Mechanism of Action

Central Suppression of the Medullary Cough Reflex

This domain details the action of Dextromethorphan, which involves agonism at the Sigma-1 (sigma1) receptor within the CNS. This molecular interaction elevates the neural threshold necessary to trigger the cough reflex, modulating the afferent signal input to the brainstem.

Modulation of Airway Secretion Rheology

This mechanism, primarily driven by Potassium Cresolsulfonate, affects the respiratory mucous membranes through osmotic and stimulatory action. This promotes tracheobronchial gland secretion, increasing the water content and decreasing the viscosity of mucus, which alters the kinetic properties of secretions for the mucociliary apparatus.

Enzymatic Support and Mechanistic Coordination

Lysozyme Chloride provides localized action by its hydrolytic mechanism on the peptidoglycan structure of susceptible bacteria, assisting in the maintenance of the local mucosal barrier structure. This peripheral action demonstrates functional coordination between the central sigma1 receptor activity and the peripheral fluid-rheology modulation.

Dosage and Administration Information

How to Use Fucou: Official Administration Guidelines

Fucou is structured for oral administration only as an immediate-release capsule. The usage protocol is defined by specific unit amounts and a time-bound schedule established for combination antitussive products.

Administration Scope

Instruction Detail
Route of administration Oral, via swallowing.
Dosing schedule The standard adult single dose is two capsules, providing 40 mg of Dextromethorphan HBr.
Frequency and timing Taken three times daily, maintaining an appropriate interval of approximately eight hours between administrations.
Timing in relation to meals May be administered with or without food.
Preparation requirements Capsules must be swallowed whole using a liquid; they should not be crushed, cut, or chewed.
Age-group administration rules The product is generally labeled for adult use. Regulatory standards for combination antitussives usually do not recommend use in very young children.
Special procedural conditions Administration is strictly for a short-term course, typically limited to a maximum of seven days.

Connection to the Overall Use Protocol

The official instructions define a non-adjustable, time-limited oral regimen that standardizes the precise multi-component dosage and its required frequency. This protocol establishes the necessary administration pattern that must be adhered to in order to conform to regulatory guidelines.

Recent Clinical Evidence

Research evidence / Overview of Studies for Fucou

The clinical research examined the Fucou combination in contexts of acute cough, typically the type of cough lasting less than three weeks and often linked to the common cold or a respiratory infection. The available evidence primarily comes from short-term Randomized Controlled Trials (RCTs). These studies were generally used in research exploring how symptoms change over time in the setting of temporary physiological imbalance.

Scope of Primary Study Outcomes

Study outcomes measured in trials included changes in cough frequency and cough severity, often monitored using patient-reported scales and objective recording devices. Research also studied outcomes related to the presence of thick secretions. Studies explored the perceived clearance of mucus and how this was associated with changes in a patient's breathing comfort. This research provides context but not individual predictions, as findings describe group patterns, not personal outcomes.

Study Comparators and Control Groups

In research exploring this specific combination, the most common study design was observed in comparisons against an active control (another single-ingredient or combination product). Consistent, placebo-controlled data for this specific triple combination are limited. Findings indicate that the overall certainty remains low regarding the contribution of all three active ingredients working together.

Gaps in the Current Research

Clinical studies for this type of product are almost entirely focused on short-term follow-up durations, typically limited to 7 days or less. This means that long-term effects are not fully established. Furthermore, data for certain groups remain insufficient, and research has not fully established patterns related to the use of Fucou in older adults or in individuals who have other pre-existing respiratory conditions. The evidence quality varies across studies, and comparative evidence is lacking in large-scale trials.

Key Studies & References

  1. Assessment of antitussive efficacy of dextromethorphan in smoking-related cough using a citric acid challenge test and subjective measures
  2. Non-prescription Oral Adult Cough, Cold and Flu Labelling Standard (Health Canada)
  3. Non-prescription Oral Adult Antitussive Cough and Cold Labelling Standard (Health Canada)

Frequently Asked Questions (FAQ)

Common questions about Fucou (FAQ)

Q: Is Fucou the same type of medicine as [Similar Drug Name]?

Fucou is classified as a fixed-dose combination product. Official information describes it as containing three active components: the cough suppressant Dextromethorphan, the expectorant Potassium Cresolsulfonate, and the enzyme Lysozyme Chloride. This composition structure provides a combined pharmacological strategy, which differentiates it from single-ingredient or dual-action preparations.

Q: Can older adults safely use Fucou?

Official regulatory documents describe a requirement for caution regarding use in older adults. This is because this population may show increased sensitivity to the central nervous system effects of the medicine, such as drowsiness or dizziness.

Q: Are there any common foods or drinks that interact with Fucou?

According to the official administration guidelines for Fucou, the medicine may be taken with or without food. The official product information does not detail specific concurrent use restrictions regarding common foods or beverages.

Q: Is it safe to drive while taking Fucou?

Regulatory documents highlight that common side effects of Fucou include dizziness and somnolence (drowsiness). Activities that require full mental alertness, such as driving or operating heavy machinery, may require caution due to the documented side effects.

Q: Can Fucou be split or crushed to make it easier to swallow?

The official administration protocol states that the capsules must be swallowed whole using a liquid. They are officially recommended not to be crushed, cut, or chewed. The administration protocol defines this method for use in accordance with regulatory guidelines.

Q: Can Fucou be used if someone is breastfeeding?

Official regulatory information states that combination products like Fucou are generally advised against during lactation. Official documents state that any use is determined by a healthcare provider.

Q: What is the mechanism of action of Fucou in simple terms?

Fucou is described in regulatory documents as working through a coordinated approach involving its three components. This action involves suppressing the central urge to cough, promoting the creation of thinner airway secretions, and providing a supportive enzymatic action to the local mucosal barrier structure.

Q: Is Fucou approved for use in children?

The official documentation indicates that the medicine is allowed for use in adult patients and children 12 years and over for the temporary relief of acute cough. Safety and efficacy have not been established for children under 4 years of age.

Q: What is the maximum duration of use for Fucou listed in official guidelines?

Official administration guidelines state that Fucou is described as being intended for a short-term course of treatment. This period is typically limited to a maximum of seven days.

How should Fucou be stored and disposed of?

The official storage conditions for Fucou (an oral solid) require the medicine to be kept at Controlled Room Temperature, typically 20 C to 25 C (68 F to 77 F), with permitted short excursions up to 30 C.

Storage Requirement Condition
Temperature 20 C to 25 C
Protection Keep tightly closed; protect from excess heat, moisture, light, and freezing.
Safety Store out of the sight and reach of children.

Disposal instructions from health authorities recommend against flushing the medicine. The best method for discarding unused or expired Fucou is utilizing a community drug take-back program. If this option is unavailable, the medicine must be removed from its container, mixed with an unappealing substance (like dirt or used coffee grounds), placed in a sealed bag, and then thrown into the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Fucou found in:

A-Z Index: